<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333565</url>
  </required_header>
  <id_info>
    <org_study_id>2014-09</org_study_id>
    <secondary_id>2014-003694-42</secondary_id>
    <secondary_id>RCAPHM14_0080</secondary_id>
    <nct_id>NCT02333565</nct_id>
  </id_info>
  <brief_title>Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas</brief_title>
  <acronym>CEVOREM</acronym>
  <official_title>Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if combination of everolimus and octreotide exert an anti-tumoral activity in&#xD;
      recurrent and/or aggressive meningiomas growth with limited adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Progression Free Survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>Measured by the number of individuals without progression disease at 6 months, according to Response Assessment in Neuro-Oncology criteria's.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Meningiomas</condition>
  <condition>Resistant Meningiomas</condition>
  <arm_group>
    <arm_group_label>Combinaison everolimus and octreotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Combinaison everolimus and octreotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <arm_group_label>Combinaison everolimus and octreotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female patients ≥ 18 years old with no maximum limited of age&#xD;
&#xD;
          -  Histologically proven meningioma grade II and III; grade I meningioma may also be&#xD;
             included, if progression is documented (see criteria 3), particularly in case of skull&#xD;
             base location&#xD;
&#xD;
          -  Progression is defined on 2 different MRI as an increase of meningioma's surface ≥ 5%&#xD;
             by 3 months period (i.e. an increase of 5% over 3 months, 10% over 6 months, 15% over&#xD;
             9 months…) or as the apparition of a new unequivocal neurological symptom related to&#xD;
             the meningioma. We considered as a new unequivocal neurological symptom a new&#xD;
             occurring neurological symptom as, for instance, hemiparesia, oculomotor nerve palsy,&#xD;
             visual loss, facial nerve palsy, facial neuralgia, directly related to meningioma and&#xD;
             suggesting meningioma growth with increase of meningioma compression on neurological&#xD;
             structures despite no increasing size on MRIs.&#xD;
&#xD;
          -  Patients must have failed surgery, and not amenable to a new curative intended surgery&#xD;
&#xD;
          -  Patients must have failed radiotherapy and/or radiosurgery&#xD;
&#xD;
          -  Prior chemotherapy is allowed, if progression under the cytotoxic agent is clearly&#xD;
             documented. An interval of 4 weeks after the last administration of the cytotoxic&#xD;
             agent is warranted. Number of prior chemotherapies is not limited.&#xD;
&#xD;
          -  Patients who have given their written consent&#xD;
&#xD;
          -  Patients affiliated to a social insurance regime&#xD;
&#xD;
          -  Adequate bone marrow function as shown by: Absolute Neutrophil Count ≥ 1.5 x 109/L,&#xD;
&#xD;
          -  Platelets ≥ 100 x 109/L, Hb &gt;9 g/dL&#xD;
&#xD;
          -  Adequate liver function as shown by; serum bilirubin ≤ 1.5 x Upper Limit of Normal;&#xD;
             International Normalized Ratio &lt; 1.3; alanine aminotransferase and aspartate&#xD;
             aminotransferase ≤ 2.5 x Upper Limit of Normal - Adequate renal function: serum&#xD;
             creatinine ≤ 1.5 x Upper Limit of Normal - Fasting serum cholesterol ≤ 300 mg/dL OR ≤&#xD;
             7.75 mmol/L and fasting triglycerides ≤ 2.5 x Upper Limit of Normal. NOTE: In case one&#xD;
             or both of these thresholds are exceeded, the patient can only be included after&#xD;
             dyslipidemia treatment initiation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic lithiasis&#xD;
&#xD;
          -  Contra indication to octreotide and everolimus&#xD;
&#xD;
          -  Women of child-bearing age who are using no effective means of contraception&#xD;
&#xD;
          -  Pregnant or breast-feeding women or adults of reproductive potential who are not using&#xD;
             effective birth control methods. If barrier contraceptives are being used, these must&#xD;
             be continued throughout the trial by both sexes&#xD;
&#xD;
          -  Patients receiving other investigational agents or who received an investigative drug&#xD;
             or therapy within the last 30 days.&#xD;
&#xD;
          -  Known intolerance or hypersensitivity to octreotide, everolimus or other rapamycin&#xD;
             (sirolimus, temsirolimus)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus defined by HbA1c&gt;8.5%&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical condition:&#xD;
&#xD;
        unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6&#xD;
        months prior to inclusion, serious uncontrolled cardiac arrhythmia, active or uncontrolled&#xD;
        severe infection, cirrhosis, chronic active hepatitis or chronic persistent hepatitis,&#xD;
        severely impaired lung function (spirometry and Diffusing Capacity of the lung for carbon&#xD;
        monoxide 50% or less of normal and O2 saturation 88% or less at rest on room air), active,&#xD;
        bleeding diathesis&#xD;
&#xD;
          -  Patients receiving chronic treatment with immunosuppressive agent&#xD;
&#xD;
          -  Patients with a known history of HIV seropositivity&#xD;
&#xD;
          -  Patients who have a history of another primary malignancy ≤ 3 years, with the&#xD;
             exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix.&#xD;
&#xD;
          -  Females patients who are pregnant or lactating, or are of childbearing potential and&#xD;
             not practicing a medically acceptable method of birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Urielle DESALBRES, Director</last_name>
    <phone>04.91.38.27.47</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GRAILLON, CCA</last_name>
      <phone>04.91.38.55.33</phone>
      <email>thomas.graillon@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 2, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

